J0717 HCPCS Level II code: Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug…
J0717 is the HCPCS code for “Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J0717Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Short description: Certolizumab pegol inj 1mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J0717 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2014
Where J0717 sits
- 1J codesDrugs administered other than orally
- 2Active code J0717Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J0717 mean?
J0717 is the HCPCS code for “Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J0717?
CMS lists J0717’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0717
All J codesJ0710Injection, cephapirin sodium, up to 1 gmJ0712Injection, ceftaroline fosamil, 10 mgJ0713Injection, ceftazidime, per 500 mgJ0714Injection, ceftazidime and avibactam, 0.5 g/0.125 gJ0715Injection, ceftizoxime sodium, per 500 mgJ0716Injection, centruroides immune f(ab)2, up to 120 milligramsJ0720Injection, chloramphenicol sodium succinate, up to 1 gmJ0725Injection, chorionic gonadotropin, per 1,000 usp unitsJ0735Injection, clonidine hydrochloride, 1 mgJ0736Injection, clindamycin phosphate, 300 mgJ0737Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mgJ0738Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)